SCHEMBL4410177

SCHEMBL4410177

C#CC[C@@H]1CCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31673078 1.00
SCHEMBL28302428 0.98 HPGD (0.35)
SCHEMBL1865680 0.93
SCHEMBL10816346 0.78 EPHX1 (0.32)
SCHEMBL8151949 0.78 EPHX1 (0.41)
SCHEMBL4442007 0.77
SCHEMBL3199236 0.77
SCHEMBL22747454 0.77
SCHEMBL10923372 0.75 KMT2A (0.41)
SCHEMBL1635831 0.74 KMT2A (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055475-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC (US) 2023-02-23 US disclosed
US-11319526-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEAGEN INC. (US) 2022-05-03 US disclosed
US-11033561-B2 Methods of inhibition of protein fucosylation in vivo using fucose analogs SEAGEN INC. (US) 2021-06-15 US disclosed
US-20200061091-A1 METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS SEATTLE GENETICS, INC. (US) 2020-02-27 US disclosed
US-10443035-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2019-10-15 US disclosed
US-20190276796-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC. 2019-09-12 US disclosed
US-10350228-B2 Treatment of sickle cell disease and inflammatory conditions SEATTLE GENETICS, INC. (US) 2019-07-16 US disclosed
US-20180155677-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC. 2018-06-07 US disclosed
US-9816069-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2017-11-14 US disclosed
US-9504702-B2 Methods of inhibition of protein fucosylation in vivo using fucose analogs SEATTLE GENETICS, INC. (US) 2016-11-29 US disclosed
US-20150337259-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEAGEN INC. 2015-11-26 US disclosed
US-20150238509-A1 TREATMENT OF SICKLE CELL DISEASE AND INFLAMMATORY CONDITIONS SEAGEN INC. 2015-08-27 US disclosed
US-8993326-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2015-03-31 US disclosed
US-20140031536-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEATTLE GENETICS, INC. (US) 2014-01-30 US disclosed
US-8574907-B2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation SEATTLE GENETICS, INC. (US) 2013-11-05 US disclosed
US-20130129784-A1 METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS SEATTLE GENETICS, INC. (US) 2013-05-23 US disclosed
US-20120183997-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEATTLE GENETICS, INC. (US) 2012-07-19 US disclosed
US-20090317869-A1 METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION SEATTLE GENETICS, INC. (US) 2009-12-24 US disclosed